{"date":"2025-08-11","count":67,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4129-2025-08-11-2024-wcl1kr","company_id":"4129","company":"聯合","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"20:24:47","subject":"公告本公司從事大陸地區投資之相關資訊","clause":"第20款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：聯合（4129），2025-08-11 20:24，「公告本公司從事大陸地區投資之相關資訊」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4129-2025-08-11-2022-bbn8ek","company_id":"4129","company":"聯合","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"20:22:37","subject":"公告本公司董事會決議轉讓子公司UOC Europe Holding SA部份股權予瑞士商SF Finance SA","clause":"第53款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：聯合（4129），2025-08-11 20:22，「公告本公司董事會決議轉讓子公司UOC Europe Holding SA部份股權予瑞士商SF Finance SA」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4129-2025-08-11-2022-xyhazt","company_id":"4129","company":"聯合","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"20:22:13","subject":"公告本公司董事會通過114年第二季合併財務報告","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：聯合（4129），2025-08-11 20:22，「公告本公司董事會通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4129-2025-08-11-2021-isqttc","company_id":"4129","company":"聯合","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"20:21:57","subject":"公告本公司董事會重要決議事項","clause":"第53款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：聯合（4129），2025-08-11 20:21，「公告本公司董事會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1783-2025-08-11-1919-92wwtj","company_id":"1783","company":"和康生","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"19:19:41","subject":"公告本公司提報董事會2025年第2季合併財務報告","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：和康生（1783），2025-08-11 19:19，「公告本公司提報董事會2025年第2季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6574-2025-08-11-1915-14xjt4y","company_id":"6574","company":"霈方","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"19:15:44","subject":"公告本公司自民國114年第3季起變更會計師事務所及簽證會計師","clause":"第7款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：霈方（6574），2025-08-11 19:15，「公告本公司自民國114年第3季起變更會計師事務所及簽證會計師」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6574-2025-08-11-1915-1x66lda","company_id":"6574","company":"霈方","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"19:15:03","subject":"本公司董事會決議第二季不分派股利","clause":"第14款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：霈方（6574），2025-08-11 19:15，「本公司董事會決議第二季不分派股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6574-2025-08-11-1914-xyhazt","company_id":"6574","company":"霈方","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"19:14:42","subject":"公告本公司董事會通過114年第二季合併財務報告","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：霈方（6574），2025-08-11 19:14，「公告本公司董事會通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6574-2025-08-11-1914-1egfkms","company_id":"6574","company":"霈方","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"19:14:19","subject":"公告本公司董事會通過重要決議","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：霈方（6574），2025-08-11 19:14，「公告本公司董事會通過重要決議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8436-2025-08-11-1911-rlixyl","company_id":"8436","company":"大江","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"19:11:36","subject":"公告本公司財務暨會計主管異動","clause":"第8款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：大江（8436），2025-08-11 19:11，「公告本公司財務暨會計主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2025-08-11-1910-gmqacw","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"19:10:50","subject":"公告本公司董事會決議通過114年第二季財務報告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：美時（1795），2025-08-11 19:10，「公告本公司董事會決議通過114年第二季財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8436-2025-08-11-1909-92wwtj","company_id":"8436","company":"大江","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"19:09:39","subject":"公告本公司提報董事會2025年第2季合併財務報告","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：大江（8436），2025-08-11 19:09，「公告本公司提報董事會2025年第2季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6541-2025-08-11-1907-1upq4ur","company_id":"6541","company":"泰福-KY","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"19:07:36","subject":"公告本公司114年現金增資收足股款暨訂定增資基準日","clause":"第51款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：泰福-KY（6541），2025-08-11 19:07，「公告本公司114年現金增資收足股款暨訂定增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4117-2025-08-11-1832-xyhazt","company_id":"4117","company":"普生","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"18:32:08","subject":"公告本公司董事會通過114年第二季合併財務報告","clause":"第43款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：普生（4117），2025-08-11 18:32，「公告本公司董事會通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4117-2025-08-11-1813-1c40ymj","company_id":"4117","company":"普生","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"18:13:53","subject":"擬調整現金增資發行價格及相關事項","clause":"第9款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：普生（4117），2025-08-11 18:13，「擬調整現金增資發行價格及相關事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4117-2025-08-11-1811-isqttc","company_id":"4117","company":"普生","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"18:11:34","subject":"公告本公司董事會重要決議事項","clause":"第44款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：普生（4117），2025-08-11 18:11，「公告本公司董事會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2025-08-11-1759-1ieu8en","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"17:59:28","subject":"本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之多國多中心樞紐三期CBL-0301(SUPREME-01)臨床試驗申請，加拿大Health Canada已核准執行。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2025-08-11 17:59，「本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之多國多中心樞紐三期CBL-0301(SUPREME-01)臨床試驗申」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2025-08-11-1758-1b16kr","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"17:58:59","subject":"代子公司共信醫藥科技股份有限公司公告向澳洲智慧財產局提出之專利申請案號數：2023285788，已獲核准通知","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2025-08-11 17:58，「代子公司共信醫藥科技股份有限公司公告向澳洲智慧財產局提出之專利申請案號數：2023285788，已獲核准通知」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7762-2025-08-11-1753-nhbes6","company_id":"7762","company":"吉晟生","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"17:53:20","subject":"公告本公司董事會通過114年第二季個別財務報告","clause":"第43款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：吉晟生（7762），2025-08-11 17:53，「公告本公司董事會通過114年第二季個別財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7762-2025-08-11-1752-1aoweer","company_id":"7762","company":"吉晟生","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"17:52:27","subject":"公告本公司董事會通過公司治理主管任命案","clause":"第11款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：吉晟生（7762），2025-08-11 17:52，「公告本公司董事會通過公司治理主管任命案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7762-2025-08-11-1751-1psi0rw","company_id":"7762","company":"吉晟生","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"17:51:54","subject":"公告本公司董事會通過技術長追認案","clause":"第11款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：吉晟生（7762），2025-08-11 17:51，「公告本公司董事會通過技術長追認案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-08-11-1742-dzpssd","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"17:42:25","subject":"公告本公司董事會決議發行114年度限制員工權利新股之增資基準日","clause":"第44款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-08-11 17:42，「公告本公司董事會決議發行114年度限制員工權利新股之增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-08-11-1741-5rax5d","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"17:41:06","subject":"公告本公司董事會決議員工認股權憑證轉換普通股增資基準日","clause":"第9款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-08-11 17:41，「公告本公司董事會決議員工認股權憑證轉換普通股增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2025-08-11-1740-1nixpbj","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"17:40:58","subject":"本公司董事會決議112年限制員工權利新股第二次配發及發行新股案","clause":"第51款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2025-08-11 17:40，「本公司董事會決議112年限制員工權利新股第二次配發及發行新股案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-08-11-1739-1axey68","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"17:39:36","subject":"代子公司朗齊株式會社公告指派總經理","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-08-11 17:39，「代子公司朗齊株式會社公告指派總經理」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2025-08-11-1739-cypi6g","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"17:39:25","subject":"本公司董事會決議辦理註銷庫藏股並訂定減資基準日","clause":"第11款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2025-08-11 17:39，「本公司董事會決議辦理註銷庫藏股並訂定減資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2025-08-11-1738-3dteg3","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"17:38:39","subject":"本公司董事會通過114年第二季合併財務報告","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2025-08-11 17:38，「本公司董事會通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-08-11-1738-1tmdycs","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"17:38:25","subject":"代子公司朗齊株式會社公告指派董事","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-08-11 17:38，「代子公司朗齊株式會社公告指派董事」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-08-11-1737-xyhazt","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"17:37:05","subject":"公告本公司董事會通過114年第二季合併財務報告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-08-11 17:37，「公告本公司董事會通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4195-2025-08-11-1735-ee45og","company_id":"4195","company":"基米-創","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"17:35:06","subject":"公告董事會通過114年第二季財務報告","clause":"第43款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：基米-創（4195），2025-08-11 17:35，「公告董事會通過114年第二季財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4195-2025-08-11-1729-8cn4p","company_id":"4195","company":"基米-創","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"17:29:42","subject":"公告本公司董事會通過(更正後)110年度起至113年度各期財務報告","clause":"第24款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：基米-創（4195），2025-08-11 17:29，「公告本公司董事會通過(更正後)110年度起至113年度各期財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7773-2025-08-11-1727-105q0ri","company_id":"7773","company":"富禾生醫","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"17:27:58","subject":"公告本公司董事會通過民國114年第二季個別財務報告","clause":"第43款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：富禾生醫（7773），2025-08-11 17:27，「公告本公司董事會通過民國114年第二季個別財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6712-2025-08-11-1725-muluxb","company_id":"6712","company":"長聖","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"17:25:05","subject":"公告本公司董事會決議通過114年第二季合併財務報告","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：長聖（6712），2025-08-11 17:25，「公告本公司董事會決議通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2025-08-11-1719-1p01rsc","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"17:19:09","subject":"公告本公司設置薪酬委員會","clause":"第6款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2025-08-11 17:19，「公告本公司設置薪酬委員會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6945-2025-08-11-1717-140kqs7","company_id":"6945","company":"圓祥生技","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"17:17:11","subject":"公告本公司董事會通過114年度第二季合併財務報告","clause":"第43款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：圓祥生技（6945），2025-08-11 17:17，「公告本公司董事會通過114年度第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4157-2025-08-11-1708-2rnx1q","company_id":"4157","company":"太景*-KY","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"17:08:45","subject":"公告114年第2季財務報告董事會召開日期為114年08月19日","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：太景*-KY（4157），2025-08-11 17:08，「公告114年第2季財務報告董事會召開日期為114年08月19日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6527-2025-08-11-1701-xyhazt","company_id":"6527","company":"明達醫","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"17:01:49","subject":"公告本公司董事會通過114年第二季合併財務報告","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：明達醫（6527），2025-08-11 17:01，「公告本公司董事會通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6527-2025-08-11-1701-go4xhv","company_id":"6527","company":"明達醫","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"17:01:27","subject":"公告本公司財務主管、會計主管及公司治理主管異動","clause":"第8款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：明達醫（6527），2025-08-11 17:01，「公告本公司財務主管、會計主管及公司治理主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6661-2025-08-11-1654-oqlgmw","company_id":"6661","company":"威健生技","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"16:54:20","subject":"公告本公司114年第2季合併財務報告經董事會通過","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：威健生技（6661），2025-08-11 16:54，「公告本公司114年第2季合併財務報告經董事會通過」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6827-2025-08-11-1652-nhbes6","company_id":"6827","company":"巨生醫","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"16:52:25","subject":"公告本公司董事會通過114年第二季個別財務報告","clause":"第43款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：巨生醫（6827），2025-08-11 16:52，「公告本公司董事會通過114年第二季個別財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3176-2025-08-11-1651-xyhazt","company_id":"3176","company":"基亞","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"16:51:40","subject":"公告本公司董事會通過114年第二季合併財務報告","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：基亞（3176），2025-08-11 16:51，「公告本公司董事會通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2025-08-11-1648-drgvb6","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"16:48:55","subject":"公告本公司累積虧損達實收資本額二分之一","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2025-08-11 16:48，「公告本公司累積虧損達實收資本額二分之一」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6917-2025-08-11-1648-1obwc2l","company_id":"6917","company":"竟天","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"16:48:31","subject":"本公司董事會決議辦理114年度現金增資發行新股","clause":"第9款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：竟天（6917），2025-08-11 16:48，「本公司董事會決議辦理114年度現金增資發行新股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6917-2025-08-11-1648-su5o6f","company_id":"6917","company":"竟天","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"16:48:04","subject":"訂定本公司限制型員工權利新股收回減資基準日","clause":"第9款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：竟天（6917），2025-08-11 16:48，「訂定本公司限制型員工權利新股收回減資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6917-2025-08-11-1647-wu9lfx","company_id":"6917","company":"竟天","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"16:47:23","subject":"本公司董事會決議通過114年第二季合併財務報告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：竟天（6917），2025-08-11 16:47，「本公司董事會決議通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4198-2025-08-11-1642-1825iv5","company_id":"4198","company":"欣大健康","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"16:42:50","subject":"本公司向關係人取得不動產使用權資產案","clause":"第20款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：欣大健康（4198），2025-08-11 16:42，「本公司向關係人取得不動產使用權資產案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4198-2025-08-11-1642-18y62m","company_id":"4198","company":"欣大健康","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"16:42:16","subject":"依公開發行公司資金貸與及背書保證處理準則第二十二條第一項第二款公告及第三款公告","clause":"第23款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：欣大健康（4198），2025-08-11 16:42，「依公開發行公司資金貸與及背書保證處理準則第二十二條第一項第二款公告及第三款公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2025-08-11-1639-1xtjtmq","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"16:39:51","subject":"公告本公司董事會通過114年第二季財務報告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2025-08-11 16:39，「公告本公司董事會通過114年第二季財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6810-2025-08-11-1631-1xtjtmq","company_id":"6810","company":"新穎生醫","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"16:31:44","subject":"公告本公司董事會通過114年第二季財務報告","clause":"第43款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：新穎生醫（6810），2025-08-11 16:31，「公告本公司董事會通過114年第二季財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6661-2025-08-11-1628-cx4zd3","company_id":"6661","company":"威健生技","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"16:28:13","subject":"公告本公司董事會決議委任第三屆薪酬委員會委員","clause":"第6款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：威健生技（6661），2025-08-11 16:28，「公告本公司董事會決議委任第三屆薪酬委員會委員」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6467-2025-08-11-1622-1f8il51","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"16:22:36","subject":"公告本公司董事會追認修訂114年員工認股權憑證發行及認股辦法","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2025-08-11 16:22，「公告本公司董事會追認修訂114年員工認股權憑證發行及認股辦法」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6467-2025-08-11-1622-1xtjtmq","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"16:22:05","subject":"公告本公司董事會通過114年第二季財務報告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2025-08-11 16:22，「公告本公司董事會通過114年第二季財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4198-2025-08-11-1621-x3cauj","company_id":"4198","company":"欣大健康","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"16:21:36","subject":"公告本公司董事會通過114年第2季合併財報務告","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：欣大健康（4198），2025-08-11 16:21，「公告本公司董事會通過114年第2季合併財報務告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6796-2025-08-11-1605-qkin3k","company_id":"6796","company":"晉弘","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"16:05:22","subject":"公告本公司取得同一有價證券一年內累積金額達公司實收資本額百分之二十","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：晉弘（6796），2025-08-11 16:05，「公告本公司取得同一有價證券一年內累積金額達公司實收資本額百分之二十」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6796-2025-08-11-1604-xyhazt","company_id":"6796","company":"晉弘","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"16:04:20","subject":"公告本公司董事會通過114年第二季合併財務報告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：晉弘（6796），2025-08-11 16:04，「公告本公司董事會通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6709-2025-08-11-1603-1q0v04","company_id":"6709","company":"昱厚生技","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"16:03:38","subject":"本公司通過TFDA審查核准執行新藥AD17002臨床二期試驗案用於治療中度至重度嗜酸性白血球型氣喘","clause":"第44款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：昱厚生技（6709），2025-08-11 16:03，「本公司通過TFDA審查核准執行新藥AD17002臨床二期試驗案用於治療中度至重度嗜酸性白血球型氣喘」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4735-2025-08-11-1554-93e1bi","company_id":"4735","company":"豪展","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"15:54:37","subject":"公告本公司董事長訂定民國114年第2季盈餘之除息基準日","clause":"第14款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：豪展（4735），2025-08-11 15:54，「公告本公司董事長訂定民國114年第2季盈餘之除息基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6610-2025-08-11-1545-lobvdf","company_id":"6610","company":"安成生技","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"15:45:17","subject":"公告本公司董事會通過113年第二季財務報告","clause":"第43款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：安成生技（6610），2025-08-11 15:45，「公告本公司董事會通過113年第二季財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6827-2025-08-11-1536-8y3vwa","company_id":"6827","company":"巨生醫","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"15:36:37","subject":"公告本公司董事會決議通過新設立子公司","clause":"第44款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：巨生醫（6827），2025-08-11 15:36，「公告本公司董事會決議通過新設立子公司」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6827-2025-08-11-1535-drgvb6","company_id":"6827","company":"巨生醫","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"15:35:47","subject":"公告本公司累積虧損達實收資本額二分之一","clause":"第44款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：巨生醫（6827），2025-08-11 15:35，「公告本公司累積虧損達實收資本額二分之一」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6637-2025-08-11-1532-wuc4cw","company_id":"6637","company":"醫影","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"15:32:05","subject":"公告本公司董事會通過股東現金股利配息基準日","clause":"第14款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：醫影（6637），2025-08-11 15:32，「公告本公司董事會通過股東現金股利配息基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6637-2025-08-11-1531-v1gwxu","company_id":"6637","company":"醫影","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"15:31:40","subject":"公告本公司調整現金股利配息率","clause":"第14款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：醫影（6637），2025-08-11 15:31，「公告本公司調整現金股利配息率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6637-2025-08-11-1531-1xtjtmq","company_id":"6637","company":"醫影","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"15:31:19","subject":"公告本公司董事會通過114年第二季財務報告","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：醫影（6637），2025-08-11 15:31，「公告本公司董事會通過114年第二季財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6621-2025-08-11-1506-nhbes6","company_id":"6621","company":"華宇藥","market":"興櫃","industry":"生技醫療","date":"2025-08-11","time":"15:06:33","subject":"公告本公司董事會通過114年第二季個別財務報告","clause":"第43款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：華宇藥（6621），2025-08-11 15:06，「公告本公司董事會通過114年第二季個別財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2025-08-11-1435-3dteg3","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"14:35:31","subject":"本公司董事會通過114年第二季合併財務報告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2025-08-11 14:35，「本公司董事會通過114年第二季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4190-2025-08-11-1431-goxvx","company_id":"4190","company":"佐登-KY","market":"上市","industry":"生技醫療","date":"2025-08-11","time":"14:31:06","subject":"公告本公司114年第二季合併財務報告董事會預計召開日期為114年8月19日","clause":"第31款","fact_date":"2025-08-11","cite_as":"公開資訊觀測站重大訊息：佐登-KY（4190），2025-08-11 14:31，「公告本公司114年第二季合併財務報告董事會預計召開日期為114年8月19日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2025-08-11-1418-11a8k14","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2025-08-11","time":"14:18:07","subject":"公告本公司收到「NALTREXONE INJECTABLE SUSTAINEDRELEASE FORMULATION」澳洲專利核准通知書。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2025-08-11 14:18，「公告本公司收到「NALTREXONE INJECTABLE SUSTAINEDRELEASE FORMULATION」澳」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}